This month, Axial Biotherapeutics announced the appointment of leading experts in the Autism Spectrum Disorders (ASD) field to its...
Read more
We are proud to announce that Kairos Venture Partners II, L.P., our second fund, has made its second investment...
Read more
We are excited to announce that Kairos Venture Partners II, L.P., our second fund, has made its first investment...
Read more
Kairos portfolio company, Compellon, appointed software and services veteran Carv Moore as its Chief Executive Officer to lead the...
Read more
The NIDDK continues to fund Delpor's efforts to utilize its NANOPOR™ technology in developing a matchstick-size subcutaneous implant device...
Read more
Delpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing...
Read more
This Seed funding allows Holoclara to continue development of their immunotherapy to bring relief to millions of people suffering...
Read more
We are pleased to announce that Neuro-Bio is the latest company to join the Kairos portfolio, following our investment...
Read more
We are delighted to announce that our portfolio company Delpor has been issued another patent by the United States...
Read more
Congratulations to our portfolio company Delpor for receiving a new grant award from the National Institute of Mental Health. The...
Read more